SEC Form SC 13G/A filed by Chiasma, Inc. (Amendment)

$CHMA
Major Pharmaceuticals
Health Care
Get the next $CHMA alert in real time by email
SC 13G/A 1 chiasma13ga.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. 1)*

 

 

Chiasma, Inc.

(Name of Issuer)

 

 

Common Stock, par value $0.01 per share

(Title of Class of Securities)

 

 

16706W102

(CUSIP Number)

 

 

May 6, 2021

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

[X]       Rule 13d-1(b)

 

[X]       Rule 13d-1(c)

 

[ ]       Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 

 1 
CUSIP No. 16706W102

 

1.Names of Reporting Persons.

Stonepine Capital Management, LLC

 

2.Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ______

(b) X

 

3. SEC Use Only

 

4.Citizenship or Place of Organization California

 

Number of

Shares

Beneficially

Owned by

Each Reporting

Person With:

5. Sole Voting Power 6,770,000

 

6. Shared Voting Power 0

 

7. Sole Dispositive Power 6,770,000
8. Shared Dispositive Power 0

 

9.Aggregate Amount Beneficially Owned by Each Reporting Person 6,770,000

 

10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions) ______

 

11.Percent of Class Represented by Amount in Row (9) 11.7%

 

12.Type of Reporting Person (See Instructions) IA, OO

 

 2 
CUSIP No. 16706W102

 

1.Names of Reporting Persons.

Stonepine Capital, L.P.

 

2.Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ______

(b) X

 

3. SEC Use Only

 

4.Citizenship or Place of Organization Delaware

 

Number of

Shares

Beneficially

Owned by

Each Reporting

Person With:

5. Sole Voting Power 6,770,000

 

6. Shared Voting Power 0

 

7. Sole Dispositive Power 6,770,000
8. Shared Dispositive Power 0

 

9.Aggregate Amount Beneficially Owned by Each Reporting Person 6,770,000

 

10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions) ______

 

11.Percent of Class Represented by Amount in Row (9) 11.7%

 

12.Type of Reporting Person (See Instructions) PN

 

 3 
CUSIP No. 16706W102

 

1.Names of Reporting Persons.

Jon M. Plexico

 

2.Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ______

(b) X

 

3. SEC Use Only

 

4.Citizenship or Place of Organization U.S.A.

 

Number of

Shares

Beneficially

Owned by

Each Reporting

Person With:

5. Sole Voting Power 6,770,000

 

6. Shared Voting Power 0

 

7. Sole Dispositive Power 6,770,000
8. Shared Dispositive Power 0

 

9.Aggregate Amount Beneficially Owned by Each Reporting Person 6,770,000

 

10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions) ______

 

11.Percent of Class Represented by Amount in Row (9) 11.7%

 

12.Type of Reporting Person (See Instructions) HC, IN

 

 4 
CUSIP No. 16706W102

 

1.Names of Reporting Persons.

Timothy P. Lynch

 

2.Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ______

(b) X

 

3. SEC Use Only

 

4.Citizenship or Place of Organization U.S.A.

 

Number of

Shares

Beneficially

Owned by

Each Reporting

Person With:

5. Sole Voting Power 6,770,000

 

6. Shared Voting Power 0

 

7. Sole Dispositive Power 6,770,000
8. Shared Dispositive Power 0

 

9.Aggregate Amount Beneficially Owned by Each Reporting Person 6,770,000

 

 

10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions) ______

 

11.Percent of Class Represented by Amount in Row (9) 11.7%

 

12.Type of Reporting Person (See Instructions) HC, IN

 5 
CUSIP No. 16706W102

 

Item 1.

 

(a)Name of Issuer

Chiasma, Inc.

 

(b)Address of Issuer’s Principal Executive Offices

140 Kendrick Street, Building C East, Needham, MA 02494

 

 

Item 2.

 

(a)The names of the persons filing this statement are:

Stonepine Capital Management, LLC, a California limited liability company (the “General Partner”)

 

Stonepine Capital, L.P., a Delaware limited partnership (the “Partnership”)

 

Jon M. Plexico

 

Timothy P. Lynch (collectively, the “Filers”)

 

The General Partner is the general partner and investment adviser of investment funds, including the Partnership. Mr. Plexico and Mr. Lynch are the control persons of the General Partner. The Filers are filing this Schedule 13G jointly, but not as members of a group, and each disclaims membership in a group. Each Filer also disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

 

(b)The principal business office of the Filers is located at

 

919 NW Bond Street, Suite 204

Bend, OR 97703-2767

 

(c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

 

(d)This statement relates to the Issuer’s Common Stock, par value $0.01 per share (the “Stock”).

 

(e)The CUSIP number of the Issuer is: 16706W102

 

 6 
CUSIP No. 16706W102
Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

(a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

 

(b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

 

(c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

 

(d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

 

(e)[ X ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E). As to the General Partner.

 

(f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

 

(g)[ X ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G). As to Mr. Plexico and Mr. Lynch.

 

(h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

 

(i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

 

(j)[ ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J).

 

(k)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

 

If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution _______________________________________________________________.

 

Item 4.Ownership.

 

See Items 5-9 and 11 of the cover page for each Filer.

 

Item 5.Ownership of Five Percent or Less of a Class

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

 

Item 6.Ownership of More than Five Percent on Behalf of Another Person.

 

The Partnership holds the Stock for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock.

 

Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

 

Not applicable.

 7 
CUSIP No. 16706W102

 

Item 8.Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9.Notice of Dissolution of Group

 

Not applicable.


Item 10.
Material to Be Filed as Exhibits

Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G.

Item 11.Certification of the General Partner, Mr. Plexico and Mr. Lynch

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Certification of the Partnership

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

 8 
CUSIP No. 16706W102

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: May 14, 2021

 

 

STONEPINE CAPITAL MANAGEMENT, LLC


By: /s/ Timothy P. Lynch
Managing Member

 

 

STONEPINE CAPITAL, L.P.

By: Stonepine Capital Management, LLC,
General Partner

By: /s/ Timothy P. Lynch
Managing Member

 

 
/s/ Jon M. Plexico
 

 


/s/ Timothy P. Lynch

 

 9 
CUSIP No. 16706W102

EXHIBIT A

 

AGREEMENT REGARDING JOINT FILING

OF STATEMENT ON SCHEDULE 13D OR 13G

 

The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Stonepine Capital Management, LLC, a California limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

 

Dated: May 15, 2017

 

 

STONEPINE CAPITAL MANAGEMENT, LLC


By: /s/ Timothy P. Lynch
Managing Member

 

 

STONEPINE CAPITAL, L.P.

By: Stonepine Capital Management, LLC,
General Partner

By: /s/ Timothy P. Lynch
Managing Member

 

 
/s/ Jon M. Plexico
 

 


/s/ Timothy P. Lynch

 

 

 

Get the next $CHMA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CHMA

DatePrice TargetRatingAnalyst
More analyst ratings

$CHMA
Press Releases

Fastest customizable press release news feed in the world

See more
  • Amryt Reports Q3 2022 Financial and Operational Results

    Amryt Reports Q3 2022 Financial and Operational Results 8.2% YoY revenue growth in Q3 to $61.1M - 12.5% on a constant currency basis 11th consecutive quarter of positive EBITDA generation; $12.5M in Q3 2022 Operating cash flows of $14.3M for Q3 2022 Cash of $83.4M at September 30, 2022 Mycapssa® revenues increased 26.9% QoQ to $5.7M and 292.8% YoY CHMP positive opinion for Mycapssa® for the treatment of acromegaly in the EU Pathway agreed with the FDA to initiate a Phase 3 study for NET - expected in Q1 2023 Filsuvez® European launch progressing well Significant metreleptin LATAM $8.3M tender won - revenue expected to be recognized in Q4 Reaffirming FY 2022 revenue guidance to $26

    $AMYT
    $CHMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals
  • Amryt Reports Record Q2 2022 Results

    Amryt Reports Record Q2 2022 Results 9.2% YoY revenue growth in Q2 to $68.5M 35.3% YoY revenue growth in Q2 excluding impact of a sporadic LATAM order in Q2 2021 7.8% growth in metreleptin revenues YoY to $46.4M in Q2 49.9% growth in metreleptin revenues in Q2 excluding impact of a sporadic LATAM order in Q2 2021 10th consecutive quarter of positive EBITDA generation Cash of $90.7M at June 30, 2022 Filsuvez® approved in the EU for the treatment of dystrophic and junctional EB Amryt now has four growing commercial products treating rare diseases Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth Stock repurchase program underway

    $AMYT
    $CHMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals
  • SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer

    Novel Vaccine Company Expands Leadership Team and Establishes US Presence SpyBiotech, a British biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Mark Leuchtenberger as its Chief Executive Officer (CEO). He also joins the Board of Directors. Sumi Biswas, the company's co-founder, remains President and a Director and becomes Chief Scientific Officer (CSO). With the addition of Leuchtenberger, SpyBiotech establishes its presence in the United States with an office in Cambridge, Massachusetts. Mark Leuchtenberger recently served as Executive Chairman for Aleta Biotherapeutics and previously as CEO o

    $CHMA
    $NRSN
    Major Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

$CHMA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CHMA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CHMA
SEC Filings

See more

$CHMA
Leadership Updates

Live Leadership Updates

See more
  • SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer

    Novel Vaccine Company Expands Leadership Team and Establishes US Presence SpyBiotech, a British biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Mark Leuchtenberger as its Chief Executive Officer (CEO). He also joins the Board of Directors. Sumi Biswas, the company's co-founder, remains President and a Director and becomes Chief Scientific Officer (CSO). With the addition of Leuchtenberger, SpyBiotech establishes its presence in the United States with an office in Cambridge, Massachusetts. Mark Leuchtenberger recently served as Executive Chairman for Aleta Biotherapeutics and previously as CEO o

    $CHMA
    $NRSN
    Major Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations
  • Pulmatrix appoints Director Anand Varadan

    LEXINGTON, Mass., July 27, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced the appointment of Anand Varadan to its Board of Directors, effective July 26, 2021. Mr. Varadan brings expertise in commercialization and successful product launches. In addition, Mark Iwicki stepped down from his role on the Board of Directors effective July 23, 2021. "We are delighted to welcome Anand to

    $PULM
    $CHMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals
  • Chiasma Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update

    Phased launch of MYCAPSSA® progressing with 2020 net product revenue of $1.1 million Achieved payor coverage of MYCAPSSA for over 150 million lives Company to host conference call today, March 4, 2021 at 5:00pm ET NEEDHAM, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to reduce the burden of chronic injections for people with rare diseases, as evidenced by its recent initiation of a phased U.S. commercial launch of MYCAPSSA® as the first oral therapy for treatment of acromegaly, today announced financial results for the fourth quar

    $CHMA
    Major Pharmaceuticals
    Health Care

$CHMA
Financials

Live finance-specific insights

See more
  • Amryt Reports Q3 2022 Financial and Operational Results

    Amryt Reports Q3 2022 Financial and Operational Results 8.2% YoY revenue growth in Q3 to $61.1M - 12.5% on a constant currency basis 11th consecutive quarter of positive EBITDA generation; $12.5M in Q3 2022 Operating cash flows of $14.3M for Q3 2022 Cash of $83.4M at September 30, 2022 Mycapssa® revenues increased 26.9% QoQ to $5.7M and 292.8% YoY CHMP positive opinion for Mycapssa® for the treatment of acromegaly in the EU Pathway agreed with the FDA to initiate a Phase 3 study for NET - expected in Q1 2023 Filsuvez® European launch progressing well Significant metreleptin LATAM $8.3M tender won - revenue expected to be recognized in Q4 Reaffirming FY 2022 revenue guidance to $26

    $AMYT
    $CHMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals
  • Amryt Reports Record Q2 2022 Results

    Amryt Reports Record Q2 2022 Results 9.2% YoY revenue growth in Q2 to $68.5M 35.3% YoY revenue growth in Q2 excluding impact of a sporadic LATAM order in Q2 2021 7.8% growth in metreleptin revenues YoY to $46.4M in Q2 49.9% growth in metreleptin revenues in Q2 excluding impact of a sporadic LATAM order in Q2 2021 10th consecutive quarter of positive EBITDA generation Cash of $90.7M at June 30, 2022 Filsuvez® approved in the EU for the treatment of dystrophic and junctional EB Amryt now has four growing commercial products treating rare diseases Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth Stock repurchase program underway

    $AMYT
    $CHMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals
  • Amryt Reports Record Q1 2022 Results

    Amryt Reports Record Q1 2022 Results CHMP adopts positive opinion for Filsuvez® for the treatment of Dystrophic and Junctional EB Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth Board approved stock repurchase program of up to $30M Cash of $102.2M at March 31, 2022 22.1% YoY revenue growth in Q1 to $59.1M 25.7% growth in metreleptin revenues YoY to $37.6M in Q1 9th consecutive quarter of positive EBITDA generation Successful bioavailability study supporting development of Mycapssa® for carcinoid symptoms in NET Conference call and webcast today at 0830 ET / 1330 BST DUBLIN, Ireland, and Boston MA, May 4, 2022, Amryt (NASDAQ:AMYT), a global, c

    $AMYT
    $CHMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals

$CHMA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more